| Bioactivity | SLC7A11-IN-2 (Compound 1) is an SLC7A11/xCT inhibitor. SLC7A11-IN-2 induces cell death in HeLa cells by lowering intracellular glutathione levels and increasing oxidative stress, thereby disrupting the oxidative balance within the cells, with an IC50 value of 10.23 μM. Molecular dynamics simulation analysis indicates that SLC7A11-IN-2 has a stronger binding affinity to SLC7A11 compared to Erastin (HY-15763). SLC7A11-IN-2 can be utilized in research within the field of cervical cancer[1]. |
| CAS | 14668-59-8 |
| Formula | C19H24N4O3 |
| Molar Mass | 356.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yue J, et al. Discovery of the Inhibitor Targeting the SLC7A11/xCT Axis through In Silico and In Vitro Experiments. Int J Mol Sci. 2024 Jul 29;25(15):8284. |
SLC7A11-IN-2
CAS: 14668-59-8 F: C19H24N4O3 W: 356.42
SLC7A11-IN-2 (Compound 1) is an SLC7A11/xCT inhibitor. SLC7A11-IN-2 induces cell death in HeLa cells by lowering intrace
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.